血清甲胎蛋白、甲胎蛋白异质体、磷脂酰肌醇蛋白聚糖-3联合诊断肝细胞肝癌的临床价值

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (398 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the clinical value of serum alpha-fetoprotein (AFP), alpha-fetoprotein-L3 (AFP-L3)and glypican-3 (GPC3) in the combined diagnosis of hepatocellular carcinoma (HCC). Methods A total of 136 Patients with suspected HCC diagnosis in the People′s Hospital of Huadu District, Guangzhou City from April 2018 to March 2021 were selected as the HCC group, 129 patients with benign liver diseases were selected as the benign group, and 140 patients with hepatitis and cirrhosis treated in the People′s Hospital of Huadu District, Guangzhou City during the same period were selected as the control group. The serum levels of AFP, AFP-L3, and GPC3 in the three groups were detected and compared. Postoperative liver biopsy was used as the gold standard to evaluate the value of AFP, AFPL3, and GPC3 for the diagnosis of HCC alone or in combination. Results The levels of AFP, AFP-L3, and GPC3 in the HCC group were higher than those in the benign group and the control group, and the levels of AFP, AFP-L3 and GPC3 in the benign group were higher than those in the control group,and the differences were statistically significant(P<0.05).The sensitivity, specificity, negative predictive value, positive predictive value and accuracy of AFP, AFP-L3, and GPC3 combined diagnosis for HCC were higher than AFP, AFP-L3, and GPC3 alone or in combination. Conclusion Serum AFP, AFP-L3, and GPC3 are closely related to HCC. Detection of their levels is helpful for the clinical diagnosis of HCC, and combined detection of the three can significantly improve the diagnosis rate of HCC.

Key words： Alpha-fetoprotein Alpha-fetoprotein-L3;Ferritin Hepatocellular carcinoma

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Hui
	ZHAO Juan
	XU Peiyan
	ZHANG Chengfang
	TAN Lijuan
	LIU Meisan

Cite this article:

LI Hui,ZHAO Juan,XU Peiyan, et al. Clinical value of combination of serum alpha-fetoprotein, alpha-fetoprotein heterosomes and phosphatidylinositol proteoglycan 3 in the diagnosis of hepatocellular carcinoma[J]. 中国当代医药, 2022, 29(9): 66-69.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I9/66

[1]	Yang JD，Hainaut P，Gores GJ，et al.A global view of hepatocellular carcinoma：trends，risk，prevention and management[J].Nat Rev Gastroenterol Hepatol，2019，16（10）：589-604.
[2]	Li Z，Zhu JY.Hepatocellular carcinoma：Current situation and challenge[J].Hepatobiliary Pancreat Dis Int，2019，18（4）：303-304.
[3]	Yang JD，Liu MC，Kisiel JB.Circulating Tumor DNA and Hepatocellular Carcinoma[J].Semin Liver Dis，2019，39（4）：452-462.
[4]	中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范（2019年版）[J].中华肝脏病杂志，2020，28（2）：112-128.
[5]	Cai Z，Chen G，Zeng Y，et al.Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma[J].Clin Cancer Res，2019，25（17）：5284-5294.
[6]	Yang T，Xing H，Wang G，et al.A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B[J].Clin Chem，2019，65（12）：1543-1553.
[7]	Di Tommaso L，Spadaccini M，Donadon M，et al.Role of liver biopsy in hepatocellular carcinoma[J].World J Gastroenterol，2019，25（40）：6041-6052.
[8]	Yoon JS，Sinn DH，Lee JH，et al.Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate -Stage Hepatocellular Carcinoma：A Multi-Cohort Study[J].Cancers （Basel），2019，11（11）：1721.
[9]	Debes JD，Carrera E，Mattos AZ，et al.Hepatocellular carcinoma，a unique tumor with a lack of biomarkers[J].Ann Hepatol，2019，18（6）：786-787.
[10]	Luo P，Wu S，Yu Y，et al.Current Status and Perspective Biomarkers in AFP Negative HCC：Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage[J].Pathol Oncol Res，2020，26（2）：599-603.
[11]	Banales JM，Inarrairaegui M，Arbelaiz A，et al.Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma，Hepatocellular Carcinoma，and Primary Sclerosing Cholangitis[J].Hepatology，2019，70（2）：547-562.
[12]	Zhang J，Chen G，Zhang P，et al.The threshold of alphafetoprotein （AFP） for the diagnosis of hepatocellular carcinoma：A systematic review and meta-analysis[J].PLoS One，2020，15（2）：e0228857.
[13]	郭鸿雁，刘庆峰，王蕊，等.血清GP73、AFP 和AFP-L3 联合检测诊断原发性肝癌的可行性研究[J].中国肿瘤临床与康复，2018，25（8）：908-911.
[14]	Qi F，Zhou A，Yan L，et al.The diagnostic value of PIVKA-Ⅱ，AFP，AFP-L3，CEA，and their combinations in primary and metastatic hepatocellular carcinoma[J].J Clin Lab Anal，2020，34（5）：e23158.
[15]	Yan ML，Yue C，Wen CC，et al.Combined detection of AFP-L3，GP73 and TIP30 enhances diagnostic accuracy for HBV-related cirrhosis and hepatocellular carcinoma[J].J Pak Med Assoc，2019，69（9）：1279-1286.
[16]	曾繁利，王东和，苏锐，等.AFP、AFP-L3 和DKK1 联合检测对原发性肝癌的诊断价值[J].川北医学院学报，2020，35（1）：130-132.
[17]	覃文周，曾灏，翚缨.肝癌早期诊断标志物的研究进展[J].中国医药科学，2020，10（24）：47-50.
[18]	李薇薇.血清甲胎蛋白、甲胎蛋白异质体、异常凝血酶原、鳞状细胞癌抗原联合检测对肝细胞癌的诊断价值[J].中国当代医药，2020，27（22）：94-96，100，254.
[19]	Montalbano M，Georgiadis J，Masterson AL，et al.Biology and function of glypican-3 as a candidate for early cancerous transformation of hepatocytes in hepatocellular carcinoma （Review）[J].Oncol Rep，2017，37（3）：1291-1300.
[23]	王艳，田保国，赵先文，等.原发性肝癌中磷脂酰肌醇蛋白聚糖3 水平及其临床意义[J].肿瘤研究与临床，2020，32（7）：485-488.
[20]	El-Saadany S，El-Demerdash T，Helmy A，et al.Diagnostic Value of Glypican-3 for Hepatocellular Carcinomas[J].Asian Pac J Cancer Prev，2018，19（3）：811-817.
[21]	Cao W，Sharma M，Imam R，et al.Study on Diagnostic Values of Astrocyte Elevated Gene 1 （AEG-1）and Glypican 3（GPC-3）in Hepatocellular Carcinoma[J].Am J Clin Pathol，2019，152（5）：647-655.
[22]	Ge S，Wang D，Lv B，et al.HCRP1，ID4 and Glypican-3：an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma[J].Int J Clin Exp Pathol，2018，11（12）：5774-5782.